Skip to main content
SpringerLink
Log in

Chronic Kidney Disease (CKD) in Cancer Patients

  • Chapter
  • First Online:
Onconephrology

  • 979 Accesses

Abstract

In this chapter, we discuss the bidirectional relationship between the various malignancies (solid organ and hematologic) and chronic kidney disease (CKD). We then discuss the importance of screening for CKD in the cancer patient, and various methods by which screening can be conducted. We review key aspects of the clinical management of patients with CKD and highlight issues unique in cancer patient with CKD, including drug dosing, hypertension, metabolic bone disease, anemia, risks of radiographic imaging, nutrition, renal replacement therapy, and conservative management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACE:

Angiotensin converting enzyme

AKI:

Acute kidney injury

ARB:

Angiotensin II receptor blocker

CKD:

Chronic kidney disease

CIN:

Contrast induced nephropathy

ESA:

Erythropoietin stimulating agent

ESKD:

End-stage kidney disease

FGF:

Fibroblast growth factor

GFR:

Glomerular filtration rate

HSCT:

Hematopoetic stem cell transplantation

NG:

Naso-gastric

NJ:

Naso-jejunal

PEG:

Percutaneous endoscopic gastrostomy

PTH:

Parathyroid hormone

VEGF:

Vascular endothelial growth factor

References

  1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.

    Article  CAS  PubMed  Google Scholar 

  2. KDIGO.org [Internet]. KDIGO clinical practice guidelines for evaluation and management of chronic kidney disease 2012. Accessed Jan 2015. http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf.

  3. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol. 2005;16(1):180–8.

    Article  PubMed  Google Scholar 

  4. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293(15):1868–74.

    Article  CAS  PubMed  Google Scholar 

  5. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA. 2003;289(1):76–9.

    Article  PubMed  Google Scholar 

  6. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. Cancer. 2007;110(6):1376–84.

    Article  CAS  PubMed  Google Scholar 

  7. Janus N, Launay-vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103:1815–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Blade J, Fernandez-Llama P, Bosch F, Montoliu J. Renal failure in multiple myeloma. Arch Intern Med. 1998;158:1889–93.

    Article  CAS  PubMed  Google Scholar 

  9. Knudsen LM, Hippe E, Hjortg M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207–12.

    Article  CAS  PubMed  Google Scholar 

  10. Ellis MJ, Parkih CR, Inrug JK, Kambay M, Patel UD. Chronic Kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transplant. 2008;8:2378–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007;39:223–9.

    Article  CAS  PubMed  Google Scholar 

  12. Baker KS, Armenian S, Bhatia S. Long- term consequences of hematopoietic stem cell transplantation: current state of the science. Biol Blood Marrow Transplant. 2010;16:90–6.

    Article  Google Scholar 

  13. Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol. 2003;14(1):197.

    Article  PubMed  Google Scholar 

  14. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93–9.

    Article  CAS  PubMed  Google Scholar 

  15. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol. 2010;23(3):253–62.

    PubMed  Google Scholar 

  16. Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MR. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 2009;24(10):3225–31.

    Article  PubMed  Google Scholar 

  17. Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, Craig JC. Association of CKD and cancer risk in older people. J Am Soc Nephrol. 2009;20:1341–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Iff S, Craig JC, Turner R, Wang JJ, Mitchell P, Wong G. Reduced estimated GFR and cancer mortality. AJKD. 2014;63:23–30.

    Article  PubMed  Google Scholar 

  19. Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, Stehman-Breen C, Gillen D, Bleyer AJ, Hirsch C, Siscovick D, Newman AB. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol: JASN. 2005;16(12):3728–35.

    Article  CAS  PubMed  Google Scholar 

  20. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol. 2010;30(6):548–56.

    Article  PubMed  Google Scholar 

  21. Na SY, Sung JY, Chang JH, Kim S, Lee HH, Park YH, Chung W, Oh KH, Jung JY. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol. 2011;33(2):121–30.

    Article  PubMed  Google Scholar 

  22. Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol: CJASN. 2011;6(5):1121–8.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Jorgensen L, Heuch I, Jenssen T, Jacobsen BK. Association of albuminuria and cancer incidence. J Am Soc Nephrol: JASN. 2008;19(5):992–8.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: morphologic observations. J Pharmacol Exp Ther. 1980;213(3):551.

    CAS  PubMed  Google Scholar 

  25. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108(17):2154–69.

    Article  PubMed  Google Scholar 

  26. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.

    Article  PubMed  Google Scholar 

  27. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41:1364–72.

    Article  PubMed  Google Scholar 

  28. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–36.

    Article  CAS  PubMed  Google Scholar 

  29. Ainsworth NL, Marshall A, Hatcher H, Whitehead L, Whitfield GA, Earl HM. Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. Ann Oncol. 2012;23(7):1845–53.

    Article  CAS  PubMed  Google Scholar 

  30. Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol. 2006;17:2120–26.

    Article  PubMed  Google Scholar 

  31. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.

    Article  CAS  PubMed  Google Scholar 

  32. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J. Evidencebased guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;31:507–20. doi:10.1001/jama.2013.284427. [Epub ahead of print]

    Article  Google Scholar 

  33. Maitland ML, Bakris GL, Black HR, Chen HX, Durand J-B, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596–604.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122–31.

    Article  PubMed  Google Scholar 

  35. Gutiérrez O, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–59.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis. 1995;25(5):663.

    Article  CAS  PubMed  Google Scholar 

  37. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):1–130.

    Google Scholar 

  38. Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. Clin Cases Miner Bone Metab. 2013;10(2):121–3.

    PubMed Central  PubMed  Google Scholar 

  39. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74: 1385–93.

    Article  CAS  PubMed  Google Scholar 

  40. Food and Drug Administration: Pamidronate Disodium 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf. Accessed Jan 2015.

  41. Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004;65:634–41.

    Article  PubMed  Google Scholar 

  42. Desikan R, Veksler Y, Raza S, et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Brit J Haematol. 2002;119:496–9.

    Article  Google Scholar 

  43. Smetana S, Michlin A, Rosenman E, et al. Pamidronate-induced nephrotoxic tubular necrosis—a case report. Clin Nephrol. 2004;61:63–7.

    Article  CAS  PubMed  Google Scholar 

  44. Buysschaert M, Cosyns JP, Barreto L, et al. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant. 2003;18:826–9.

    Article  CAS  PubMed  Google Scholar 

  45. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate. Kidney Int. 2003;64:281–9.

    Article  CAS  PubMed  Google Scholar 

  46. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377(9768):813–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.

    Article  CAS  PubMed  Google Scholar 

  48. Eschbach JW. Erythropoietin 1991—an overview. Am J Kidney Dis. 1991;18(4 Suppl 1):3–9.

    CAS  PubMed  Google Scholar 

  49. Hsu CY, McCulloch CE, Curhan G. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13(2):504–10.

    PubMed  Google Scholar 

  50. Locatelli F, Gascon P. Is nephrology more at ease than oncology with erythropoiesisstimulating agents? Treatment guidelines and an update on benefits and risks. Oncologist. 2009;14(Suppl 1):57–62.

    Article  CAS  PubMed  Google Scholar 

  51. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573–8.

    Article  Google Scholar 

  52. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25(4):548–54.

    Article  CAS  PubMed  Google Scholar 

  53. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65(3):757–67.

    Article  CAS  PubMed  Google Scholar 

  54. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.

    Article  PubMed  Google Scholar 

  55. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.

    Article  PubMed  Google Scholar 

  56. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.

    Article  CAS  PubMed  Google Scholar 

  57. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.

    Article  CAS  PubMed  Google Scholar 

  58. Henke M, Mattern D, PepeMet al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2006;24:4708–13.

    Article  CAS  PubMed  Google Scholar 

  59. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.

    PubMed  Google Scholar 

  60. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–24.

    Article  CAS  PubMed  Google Scholar 

  61. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180(11):E62–71.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–59.

    Article  CAS  PubMed  Google Scholar 

  63. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Am Soc Clin Oncol, Am Soc Hematol J Clin Oncol. 2010;28(33):4996–5010.

    Article  Google Scholar 

  64. Hazzan A, Shah H, Hong S, Sakhiya V, Wanchoo R, Fishbane S. Treatment with erythropoiesisstimulating agents in chronic kidney disease patients with cancer. Kidney Int. 2014;86:34–9. doi:10.1038/ki.2013.528. [Epub ahead of print]

    Article  CAS  PubMed  Google Scholar 

  65. Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol. 2008;3(1):273–80.

    Article  CAS  PubMed  Google Scholar 

  66. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis. Curr Opin Rheumatol. 2006;18(6):614–7.

    Article  PubMed  Google Scholar 

  67. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001;42(3):339.

    Article  CAS  PubMed  Google Scholar 

  68. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Am J Med. 1980;69(4):491–7.

    Article  CAS  PubMed  Google Scholar 

  69. Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010;29(2):154–9.

    Article  CAS  PubMed  Google Scholar 

  70. Garg AX, Blake PG, Clark WF, Clase CM, Haynes RB, Moist LM. Association between renal insufficiency and malnutrition in older adults: results from the NHANES III. Kidney Int. 2001;60(5):1867.

    Article  CAS  PubMed  Google Scholar 

  71. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevio-Becerra A, Trevinho-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391.

    Article  CAS  PubMed  Google Scholar 

  72. Isenring E, Cross G, Daniels L, Kellett E, Koczwara B. Validity of the malnutrition screening tool as an effective predictor of nutritional risk in oncology outpatients receiving chemotherapy. Support Care Cancer. 2006;14:1152–6.

    Article  PubMed  Google Scholar 

  73. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis. 2000;35(6 Suppl 2):1–40.

    Google Scholar 

  74. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. Review High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomized clinical trials. D Ann Oncol. 2001;12(3):289–300.

    Article  CAS  Google Scholar 

  75. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr. 2005;15(3):345–55.

    Article  PubMed  Google Scholar 

  76. Lichodziejewska-Niemierko M, Rutkowski B. Palliative care in nephrology. J Nephrol. 2008;21(Suppl 13):153–7.

    Google Scholar 

  77. Tamura MJ, Meier DE. Five policies to promote palliative care for patients with ESRD. Clin J Am Soc Nephrol. 2013;8:1783–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Kidney Diseases and Hypertension, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LIJ School of Medicine, 100 Community Drive, 2nd Floor, 11021, Great Neck, NY, USA

    Mala Sachdeva MD & Anna Mathew MD, MPH

  2. Section of Nephrology, Department of Emergency Medicine, UT MD Anderson Cancer Center, Houston, TX, USA

    Amit Lahoti MD

Authors
  1. Mala Sachdeva MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit Lahoti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Mathew MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mala Sachdeva MD .

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Kidney Diseases and Hypertension, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore LIJ School of Medicine, Great Neck, New York, USA

    Kenar D. Jhaveri

  2. Nephrology Section, General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Abdulla K. Salahudeen

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sachdeva, M., Lahoti, A., Mathew, A. (2015). Chronic Kidney Disease (CKD) in Cancer Patients. In: Jhaveri, K., Salahudeen, A. (eds) Onconephrology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2659-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2659-6_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2658-9

  • Online ISBN: 978-1-4939-2659-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation